Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2020

View Archived Issues

Endothelial cells have functional deficits in progeria

More enhancers suggest more pathogenicity: study

Tarsius opens two phase I/II trials of TRS-01 eye drops

Positive preclinical data presented for QPG-1029

Phase II data for arimoclomol as treatment of sporadic inclusion body myositis

Immunitor presents interim phase III data for hepcortespenlisimut-L in HCC

FASN as a new prognostic biomarker in Wilms' tumor

G-721-0282, novel CHI3L1 ligand with anti-proliferative effects in models of osteosarcoma

Chinese researchers patent PI3K inhibitors

Novartis identifies new NLRP3 inflammasome inhibitors

Japanese investigators synthesize new PTPN11 inhibitors

Hanmi Science describes new FLT3 and/or FLT3 ITD mutant inhibitors

New SNF2L2 inhibitors presented by Epizyme

ApoE, largest genetic risk factor for AD, also affects synucleinopathies

11 potential blockbuster drugs offer hope, threaten budgets

Tumor-targeted siRNA/pDNA dual delivery system reprograms the tumor microenvironment

Paraoxonase 1 gene therapy offers long-term protection against lethal doses of nerve agents in mice

Mucolipin-1 found to be a potential therapeutic target for DMD

Amgen studies AMG-509 in phase I for metastatic CRPC

PsiOxus initiates phase I study of NG-641 in metastatic or advanced epithelial tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...